Christopher M. Gomez

Christopher M. Gomez publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Christopher M. Gomez sits on this spectrum.

Christopher M. Gomez D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Christopher M. Gomez sits on this spectrum.

Best Publications

• International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome

  P. Trouillas;T. Takayanagi;M. Hallett;R.D. Currier

  1425
  Citations

• Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy

  James L. Urban;Vipin Kumar;Dwight H. Kono;Christopher Gomez

  711
  Citations

• Spinocerebellar ataxia type 6: Gaze‐evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset

  Christopher M. Gomez;Randall M. Thompson;Jason T. Gammack;Susan L. Perlman

  317
  Citations

• Dysfunction of the basal ganglia, but not the cerebellum, impairs kinaesthesia.

  Matthias Maschke;Christopher M. Gomez;Paul J. Tuite;Jürgen Konczak

  270
  Citations

• Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families

  Melinda L Moseley;K A Benzow;L J Schut;Thomas D Bird

  264
  Citations

• Second Cistron in CACNA1A Gene Encodes a Transcription Factor Mediating Cerebellar Development and SCA6

  Xiaofei Du;Jun Wang;Haipeng Zhu;Lorenzo Rinaldo

  196
  Citations

• C-termini of P/Q-type Ca2+ channel α1A subunits translocate to nuclei and promote polyglutamine-mediated toxicity

  Holly B. Kordasiewicz;Randall M. Thompson;H. Brent Clark;Christopher M. Gomez;Christopher M. Gomez

  194
  Citations

• Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia.

  L. P W Ranum;J. K. Lundgren;L. J. Schut;M. J. Ahrens

  194
  Citations

• Spinocerebellar ataxia type 6 knockin mice develop a progressive neuronal dysfunction with age-dependent accumulation of mutant CaV2.1 channels

  Kei Watase;Curtis F. Barrett;Taisuke Miyazaki;Taro Ishiguro

  186
  Citations

• The Polyglutamine Expansion in Spinocerebellar Ataxia Type 6 Causes a β Subunit-Specific Enhanced Activation of P/Q-Type Calcium Channels in Xenopus Oocytes

  Sophie Restituito;Randall M. Thompson;Jacob Eliet;Robert S. Raike

  166
  Citations

• Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; A prospective observational study

  Tetsuo Ashizawa;Karla P Figueroa;Susan L Perlman;Christopher M Gomez

  164
  Citations

• Spinocerebellar ataxia type 6

  Ana Solodkin;Christopher M Gomez

  163
  Citations

• Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia

  David P. Richman;Christopher M. Gomez;Phillip W. Berman;Steven A. Burres

  162
  Citations

• Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia

  Christopher M. Gomez;David P. Richman

  160
  Citations

• Progression of Friedreich ataxia: quantitative characterization over 5 years.

  Maya Patel;Charles J. Isaacs;Lauren Seyer;Karlla Brigatti

  157
  Citations

• FXN methylation predicts expression and clinical outcome in Friedreich ataxia.

  Marguerite V Evans-Galea;Marguerite V Evans-Galea;Nissa Carrodus;Simone M Rowley;Louise Anne Corben

  148
  Citations

• A β‐subunit mutation in the acetylcholine receptor channel gate causes severe slow‐channel syndrome

  Christopher M. Gomez;Ricardo A Maselli;Jason Gammack;Jose Lasalde

  145
  Citations

• Sharing of antigenic determinants between the nicotinic acetylcholine receptor and proteins in Escherichia coli, Proteus vulgaris, and Klebsiella pneumoniae. Possible role in the pathogenesis of myasthenia gravis.

  Kari Stefansson;Michael E. Dieperink;David P. Richman;Christopher M. Gomez

  140
  Citations

• Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.

  Lisa S. Friedman;Lisa S. Friedman;Jennifer M. Farmer;Jennifer M. Farmer;Susan Perlman;George Wilmot

  136
  Citations

• Monoclonal antibodies against purified nicotinic acetylcholine receptor

  Christopher M. Gomez;David P. Richman;Phillip W. Berman;Steven A. Burres

  131
  Citations